These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2072413)

  • 21. Alterations of p53 gene in soft tissue and bone tumors.
    Roessner A; Schneider-Stock R; Radig K; Neumann W; Mittler U
    Gen Diagn Pathol; 1997 Jul; 143(1):1-13. PubMed ID: 9269903
    [No Abstract]   [Full Text] [Related]  

  • 22. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products.
    Mashiyama S; Murakami Y; Yoshimoto T; Sekiya T; Hayashi K
    Oncogene; 1991 Aug; 6(8):1313-8. PubMed ID: 1886708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The tumor suppressor gene p53 (part 2). Applications in human pathology].
    Martin A
    Ann Pathol; 1995; 15(3):184-91. PubMed ID: 7639854
    [No Abstract]   [Full Text] [Related]  

  • 24. p53: from clinical significance to significance in the clinic?
    Hall AR; Braithwaite A
    N Z Med J; 1997 Sep; 110(1052):347-8. PubMed ID: 9364174
    [No Abstract]   [Full Text] [Related]  

  • 25. Colon cancer: p53 expression and DNA ploidy. Their relation to proximal or distal tumor site.
    García-Hirschfeld García J; Blanes Berenguel A; Vicioso Recio L; Márquez Moreno A; Rubio Garrido J; Matilla Vicente A
    Rev Esp Enferm Dig; 1999 Jul; 91(7):481-8. PubMed ID: 10477366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Why have we only two P53 genes?].
    Weill JC
    Med Sci (Paris); 2017 Nov; 33(11):997-999. PubMed ID: 29200399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour suppressor genes: nature's defence against cancer.
    Robinson A
    CMAJ; 1993 Aug; 149(3):310-3. PubMed ID: 8339177
    [No Abstract]   [Full Text] [Related]  

  • 28. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
    Greenblatt MS; Bennett WP; Hollstein M; Harris CC
    Cancer Res; 1994 Sep; 54(18):4855-78. PubMed ID: 8069852
    [No Abstract]   [Full Text] [Related]  

  • 29. Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia.
    Fujii S; Fujimori T; Chiba T
    J Exp Clin Cancer Res; 2003 Mar; 22(1):107-15. PubMed ID: 12725330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
    Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
    Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The importance of a SNiP of the MDM2 gene to modulate the p53 pathway and the predisposition to cancer].
    Larsen CJ
    Bull Cancer; 2011 Jan; 98(1):10. PubMed ID: 21591298
    [No Abstract]   [Full Text] [Related]  

  • 32. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes.
    Tsuda H; Hirohashi S
    Jpn J Cancer Res; 1992 Nov; 83(11):1184-91. PubMed ID: 1336492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
    Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
    Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TP53 mutations on circulating cell-free DNA.
    Pantel K
    EBioMedicine; 2016 Aug; 10():15-6. PubMed ID: 27412263
    [No Abstract]   [Full Text] [Related]  

  • 36. p53 as a therapeutic target.
    Staples OD; Steele RJ; Lain S
    Surgeon; 2008 Aug; 6(4):240-3. PubMed ID: 18697367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From gene to carcinogen: a rapidly evolving field in molecular epidemiology.
    Jones PA; Buckley JD; Henderson BE; Ross RK; Pike MC
    Cancer Res; 1991 Jul; 51(13):3617-20. PubMed ID: 2054797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 abnormality and tumor invasion in patients with malignant astrocytoma.
    Momota H; Narita Y; Matsushita Y; Miyakita Y; Shibui S
    Brain Tumor Pathol; 2010 Oct; 27(2):95-101. PubMed ID: 21046311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dual role of mutant p53 protein in chemosensitivity of human cancers.
    Mueller H; Eppenberger U
    Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [P53 mutations, asset or disadvantage for cancer chemotherapy].
    Jacquemin-Sablon A
    Bull Cancer; 1997 Jul; 84(7):741-6. PubMed ID: 9339201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.